CN116212030A - 包含阿兹夫定的抗肿瘤药物组合物 - Google Patents

包含阿兹夫定的抗肿瘤药物组合物 Download PDF

Info

Publication number
CN116212030A
CN116212030A CN202310201580.XA CN202310201580A CN116212030A CN 116212030 A CN116212030 A CN 116212030A CN 202310201580 A CN202310201580 A CN 202310201580A CN 116212030 A CN116212030 A CN 116212030A
Authority
CN
China
Prior art keywords
tumor
cancer
egfr
pharmaceutical combination
azvudine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310201580.XA
Other languages
English (en)
Chinese (zh)
Inventor
李磐
贾丽敏
秦志勇
王朝阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Genuine Biotech Co Ltd
Original Assignee
Henan Genuine Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Genuine Biotech Co Ltd filed Critical Henan Genuine Biotech Co Ltd
Priority to CN202310201580.XA priority Critical patent/CN116212030A/zh
Priority to US18/199,402 priority patent/US11878028B1/en
Priority to EP23174301.4A priority patent/EP4424310B1/en
Priority to JP2023083308A priority patent/JP7783217B2/ja
Publication of CN116212030A publication Critical patent/CN116212030A/zh
Priority to TW113107353A priority patent/TW202435855A/zh
Priority to KR1020257033469A priority patent/KR20250166964A/ko
Priority to PCT/CN2024/079625 priority patent/WO2024183644A1/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202310201580.XA 2023-03-03 2023-03-03 包含阿兹夫定的抗肿瘤药物组合物 Pending CN116212030A (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202310201580.XA CN116212030A (zh) 2023-03-03 2023-03-03 包含阿兹夫定的抗肿瘤药物组合物
US18/199,402 US11878028B1 (en) 2023-03-03 2023-05-19 Anti-tumor pharmaceutical composition comprising azvudine
EP23174301.4A EP4424310B1 (en) 2023-03-03 2023-05-19 Anti-tumor pharmaceutical composition comprising azvudine and an egfr/tki inhibitor
JP2023083308A JP7783217B2 (ja) 2023-03-03 2023-05-19 アズブジンを含む抗腫瘍医薬組成物
TW113107353A TW202435855A (zh) 2023-03-03 2024-03-01 包含阿茲夫定的抗腫瘤藥物組合物
KR1020257033469A KR20250166964A (ko) 2023-03-03 2024-03-01 아즈부딘을 포함한 항종양 약학적 조성물
PCT/CN2024/079625 WO2024183644A1 (zh) 2023-03-03 2024-03-01 包含阿兹夫定的抗肿瘤药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310201580.XA CN116212030A (zh) 2023-03-03 2023-03-03 包含阿兹夫定的抗肿瘤药物组合物

Publications (1)

Publication Number Publication Date
CN116212030A true CN116212030A (zh) 2023-06-06

Family

ID=86468723

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310201580.XA Pending CN116212030A (zh) 2023-03-03 2023-03-03 包含阿兹夫定的抗肿瘤药物组合物

Country Status (7)

Country Link
US (1) US11878028B1 (https=)
EP (1) EP4424310B1 (https=)
JP (1) JP7783217B2 (https=)
KR (1) KR20250166964A (https=)
CN (1) CN116212030A (https=)
TW (1) TW202435855A (https=)
WO (1) WO2024183644A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024183644A1 (zh) * 2023-03-03 2024-09-12 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116196325A (zh) * 2023-03-10 2023-06-02 河南真实生物科技有限公司 包含阿兹夫定的免疫调节剂组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000103A (zh) * 2009-12-21 2011-04-06 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
CN106236715A (zh) * 2015-06-03 2016-12-21 南京三迭纪医药科技有限公司 药品剂型及其使用
US20170296541A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with egfr inhibitors
CN114191558A (zh) * 2020-09-17 2022-03-18 上海翰森生物医药科技有限公司 Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途
CN115006397A (zh) * 2021-03-05 2022-09-06 上海翰森生物医药科技有限公司 一种预防或治疗肿瘤疾病的药物用途
US20230056604A1 (en) * 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
TWI818007B (zh) * 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI762784B (zh) * 2018-05-23 2022-05-01 大陸商江蘇恒瑞醫藥股份有限公司 Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
EP3954682A4 (en) * 2019-04-09 2022-10-12 Henan Genuine Biotech Co., Ltd. 2-(2,4,5-substituted phenylamino)pyrimidine derivative and crystal form b thereof
CN110003183A (zh) * 2019-04-09 2019-07-12 河南真实生物科技有限公司 2-（2，4，5-取代苯氨基）嘧啶衍生物及其晶形b
CN114569728B (zh) * 2020-11-30 2023-11-28 诺未科技（北京）有限公司 一种组合物及其应用和药物
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000103A (zh) * 2009-12-21 2011-04-06 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
CN106236715A (zh) * 2015-06-03 2016-12-21 南京三迭纪医药科技有限公司 药品剂型及其使用
US20170296541A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with egfr inhibitors
US20230056604A1 (en) * 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN114191558A (zh) * 2020-09-17 2022-03-18 上海翰森生物医药科技有限公司 Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途
CN115006397A (zh) * 2021-03-05 2022-09-06 上海翰森生物医药科技有限公司 一种预防或治疗肿瘤疾病的药物用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024183644A1 (zh) * 2023-03-03 2024-09-12 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Also Published As

Publication number Publication date
JP7783217B2 (ja) 2025-12-09
EP4424310A1 (en) 2024-09-04
JP2024125139A (ja) 2024-09-13
WO2024183644A1 (zh) 2024-09-12
KR20250166964A (ko) 2025-11-28
EP4424310C0 (en) 2025-07-16
US11878028B1 (en) 2024-01-23
EP4424310B1 (en) 2025-07-16
TW202435855A (zh) 2024-09-16

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
CN113301895B (zh) 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途
RU2429838C2 (ru) Комбинированная химиотерапия
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
WO2024183644A1 (zh) 包含阿兹夫定的抗肿瘤药物组合物
TWI754170B (zh) Ｊａｋ激酶抑制劑與ｅｇｆｒ抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN111558044B (zh) 一种包含舒尼替尼的药物组合物及其制剂和应用
TW202435896A (zh) 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物
US20170173023A1 (en) Combination therapy with volasertib
US20210145834A1 (en) Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
JP7381115B2 (ja) 組成物及びがん治療用医薬品の調製におけるその応用
JP2005255643A (ja) 抗腫瘍効果増強方法および抗腫瘍効果増強剤
CN113679720B (zh) 一种取代丁烯酰胺联合铂类化合物的药物组合物及其用途
US12336996B2 (en) Drug combination containing TLR7 agonist
CN114569619A (zh) Pi3k抑制剂单用或联合egfr抑制剂在制备治疗头颈癌或胃癌的药物中的用途
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
CN115040523A (zh) Pi3k抑制剂联合雌激素受体拮抗剂在治疗肿瘤疾病中的用途
CN111821304A (zh) 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途
WO2008064596A1 (fr) Composition pharmaceutique comprenant la protéine p43 pour le traitement de l'adénocarcinome gastrique
EA040162B1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination